Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMDANASDAQ:GNTANASDAQ:IPSCNASDAQ:JSPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMDAGamida Cell$0.17$0.03▼$2.51$5.04M0.939.20 million shs23.04 million shsGNTAGenenta Science$3.11-4.9%$4.10$2.79▼$7.28$59.81M0.7315,194 shs33,187 shsIPSCCentury Therapeutics$0.59-0.8%$0.55$0.34▼$3.29$50.94M1.77529,386 shs262,322 shsJSPRJasper Therapeutics$5.26-2.8%$4.98$3.13▼$26.05$81.27M2.72302,869 shs172,163 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMDAGamida Cell0.00%0.00%0.00%0.00%0.00%GNTAGenenta Science-7.37%-34.40%-23.06%-15.06%-0.91%IPSCCentury Therapeutics+1.93%-6.87%+5.57%+1.41%-81.23%JSPRJasper Therapeutics-3.91%-6.24%+9.74%+4.24%-77.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMDAGamida CellN/AN/AN/AN/AN/AN/AN/AN/AGNTAGenenta Science3.031 of 5 stars3.55.00.00.02.81.70.0IPSCCentury Therapeutics2.4824 of 5 stars3.54.00.00.00.61.70.6JSPRJasper Therapeutics2.2804 of 5 stars3.52.00.00.03.11.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMDAGamida Cell 0.00N/AN/AN/AGNTAGenenta Science 3.00Buy$25.00703.86% UpsideIPSCCentury Therapeutics 3.00Buy$4.20616.23% UpsideJSPRJasper Therapeutics 3.00Buy$62.221,082.93% UpsideCurrent Analyst Ratings BreakdownLatest GMDA, GNTA, JSPR, and IPSC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025IPSCCentury TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $6.005/15/2025JSPRJasper TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$80.00 ➝ $65.005/13/2025JSPRJasper TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $33.004/3/2025IPSCCentury TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $2.003/28/2025IPSCCentury TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/24/2025IPSCCentury TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $7.003/21/2025IPSCCentury TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $5.003/20/2025IPSCCentury TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$4.00 ➝ $2.00(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMDAGamida Cell$1.78M0.00N/AN/A($0.02) per share0.00GNTAGenenta ScienceN/AN/AN/AN/A$0.74 per shareN/AIPSCCentury Therapeutics$6.59M7.67N/AN/A$1.90 per share0.31JSPRJasper TherapeuticsN/AN/AN/AN/A$4.11 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMDAGamida Cell-$63M-$0.63N/AN/AN/AN/AN/A-57.59%N/AGNTAGenenta Science-$9.64MN/A0.00N/AN/AN/AN/AN/AN/AIPSCCentury Therapeutics-$126.57M-$0.29N/AN/AN/A-19.10%-10.71%-5.96%8/14/2025 (Estimated)JSPRJasper Therapeutics-$71.27M-$5.24N/AN/AN/AN/A-109.45%-89.82%8/12/2025 (Estimated)Latest GMDA, GNTA, JSPR, and IPSC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IPSCCentury Therapeutics-$0.31$0.89+$1.20$0.89$45.52 million$109.16 million5/12/2025Q1 2025JSPRJasper Therapeutics-$1.17-$1.41-$0.24-$1.41N/AN/A3/19/2025Q4 2024IPSCCentury Therapeutics-$0.45-$0.43+$0.02-$0.43$0.67 million$4.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMDAGamida CellN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/AJSPRJasper TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMDAGamida Cell213.142.162.09GNTAGenenta ScienceN/A6.896.89IPSCCentury TherapeuticsN/A11.7011.70JSPRJasper TherapeuticsN/A4.314.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMDAGamida Cell50.34%GNTAGenenta Science15.13%IPSCCentury Therapeutics50.20%JSPRJasper Therapeutics79.85%Insider OwnershipCompanyInsider OwnershipGMDAGamida Cell3.40%GNTAGenenta Science28.99%IPSCCentury Therapeutics5.00%JSPRJasper Therapeutics4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMDAGamida Cell143154.05 million143.70 millionOptionableGNTAGenenta Science718.29 million12.99 millionNot OptionableIPSCCentury Therapeutics17086.16 million81.85 millionOptionableJSPRJasper Therapeutics2015.02 million14.33 millionOptionableGMDA, GNTA, JSPR, and IPSC HeadlinesRecent News About These CompaniesJasper Therapeutics stock maintains buy rating on positive urticaria dataJune 18 at 7:54 PM | investing.comJasper Therapeutics Reports Encouraging Results from SPOTLIGHT Phase 1b/2a Study of Briquilimab for Chronic Inducible UrticariaJune 16 at 12:25 AM | nasdaq.comJasper Therapeutics’ SWOT analysis: briquilimab’s potential in CSU stock scrutinizedJune 15 at 7:19 PM | investing.comJasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible UrticariaJune 14, 2025 | globenewswire.comCantor Fitzgerald Comments on JSPR FY2026 EarningsJune 11, 2025 | americanbankingnews.comAnalysts Offer Predictions for JSPR FY2026 EarningsJune 10, 2025 | marketbeat.comJasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual CongressJune 3, 2025 | globenewswire.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of "Buy" by BrokeragesJune 1, 2025 | marketbeat.comJasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash WiselyMay 29, 2025 | finance.yahoo.comWoodline Partners LP Decreases Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR)May 26, 2025 | marketbeat.comJasper Therapeutics, Inc. (JSPR): Analysts See 914% Upside PotentialMay 21, 2025 | insidermonkey.comSoleus Capital Management L.P. Has $31.95 Million Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR)May 21, 2025 | marketbeat.comJasper Therapeutics to Present at RBC and Jefferies Global Healthcare Conferences on Briquilimab DevelopmentMay 16, 2025 | nasdaq.comJasper Therapeutics to Present at Upcoming Investor ConferencesMay 14, 2025 | globenewswire.comJasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 12, 2025 | globenewswire.comWhy Jasper Therapeutics, Inc.’s (JSPR) Stock Is Down 5.34%May 6, 2025 | aaii.comWhy Jasper Therapeutics, Inc.’s (JSPR) Stock Is Up 7.05%April 22, 2025 | aaii.comWhy Jasper Therapeutics, Inc.’s (JSPR) Stock Is Up 7.55%April 11, 2025 | aaii.comJasper Therapeutics inks new sales agreement, ends previous dealMarch 21, 2025 | uk.investing.comJasper Therapeutics files $300M mixed securities shelfMarch 19, 2025 | markets.businessinsider.comJasper Therapeutics presents updated data from Phase 1b/2a BEACON studyMarch 2, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGMDA, GNTA, JSPR, and IPSC Company DescriptionsGamida Cell NASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.Genenta Science NASDAQ:GNTA$3.20 -0.08 (-2.29%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.Century Therapeutics NASDAQ:IPSC$0.59 0.00 (-0.81%) Closing price 04:00 PM EasternExtended Trading$0.59 +0.00 (+0.27%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Jasper Therapeutics NASDAQ:JSPR$5.26 -0.15 (-2.77%) Closing price 04:00 PM EasternExtended Trading$5.26 0.00 (-0.10%) As of 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
